Intensity Therapeutics Discloses $11.9M Preliminary Cash Balance, Zero Debt
INTS sits 66% above its 52-week low of $4.633 on light trading volume (0.2× avg).
Summary
Intensity Therapeutics disclosed preliminary unaudited financial highlights as of December 31, 2025, reporting $11.9 million in cash and cash equivalents with no debt, providing a strong liquidity position for the micro-cap biotech.
Key Events · Financing and Capital Events · INTS
-
Strong Cash Position Reported
The company reported preliminary, unaudited cash and cash equivalents of $11.9 million as of December 31, 2025.
-
Zero Debt and Low Liabilities
Intensity Therapeutics highlighted a balance sheet with no reported debt and total liabilities of $1.4 million.
-
Capitalization Table Updated Post-Split
The filing included an updated capitalization table, reflecting 2.52 million shares outstanding, restated for a 1-for-25 reverse stock split on February 19, 2026.
Analysis · INTS · Life Sciences
Intensity Therapeutics, a micro-cap life sciences company, reported preliminary unaudited financial highlights for Q4 2025, revealing a strong cash and cash equivalents balance of $11.9 million with no outstanding debt. This significant liquidity position provides a crucial financial runway for its operations and clinical development. While the figures are preliminary and subject to audit, they offer a positive indication of the company's financial health. The filing also included an updated capitalization table, adjusted for the 1-for-25 reverse stock split enacted on February 19, 2026.
At the time of this filing, INTS was trading at $7.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $4.63 to $62.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.